• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

囊性纤维化的遗传学:临床意义

Genetics of Cystic Fibrosis: Clinical Implications.

作者信息

Egan Marie E

机构信息

Department of Pediatrics, Yale School of Medicine, 333 Cedar Street, Fitkin 526, New Haven, CT 06520, USA.

出版信息

Clin Chest Med. 2016 Mar;37(1):9-16. doi: 10.1016/j.ccm.2015.11.002. Epub 2015 Dec 24.

DOI:10.1016/j.ccm.2015.11.002
PMID:26857764
Abstract

Cystic fibrosis (CF) is a common life-shortening autosomal recessive genetic disorder caused by mutations in the gene that encodes for the cystic fibrosis transmembrane conductance regulator protein (CFTR). Almost 2000 variants in the CFTR gene have been identified. The mutational classes are based on the functional consequences on CFTR. New therapies are being developed to target mutant CFTR and restore CFTR function. Understanding specific CF genotypes is essential for providing state-of-the art care to patients. In addition to the variation in CFTR genotype, there are several modifier genes that contribute to the respiratory phenotype.

摘要

囊性纤维化(CF)是一种常见的、会缩短寿命的常染色体隐性遗传病,由编码囊性纤维化跨膜传导调节蛋白(CFTR)的基因突变引起。CFTR基因中已鉴定出近2000种变体。突变类型基于对CFTR的功能影响。目前正在开发针对突变型CFTR并恢复CFTR功能的新疗法。了解特定的CF基因型对于为患者提供最先进的治疗至关重要。除了CFTR基因型的差异外,还有几种修饰基因会影响呼吸表型。

相似文献

1
Genetics of Cystic Fibrosis: Clinical Implications.囊性纤维化的遗传学:临床意义
Clin Chest Med. 2016 Mar;37(1):9-16. doi: 10.1016/j.ccm.2015.11.002. Epub 2015 Dec 24.
2
Genetics of cystic fibrosis: CFTR mutation classifications toward genotype-based CF therapies.囊性纤维化的遗传学:基于基因型的囊性纤维化治疗的CFTR突变分类
Int J Biochem Cell Biol. 2014 Jul;52:94-102. doi: 10.1016/j.biocel.2014.02.023. Epub 2014 Mar 12.
3
Lumacaftor and ivacaftor in the management of patients with cystic fibrosis: current evidence and future prospects.鲁马卡托和依伐卡托用于囊性纤维化患者的治疗:当前证据与未来前景
Ther Adv Respir Dis. 2015 Dec;9(6):313-26. doi: 10.1177/1753465815601934. Epub 2015 Sep 28.
4
The phenotypic consequences of CFTR mutations.囊性纤维化跨膜传导调节因子(CFTR)突变的表型后果。
Ann Hum Genet. 2003 Sep;67(Pt 5):471-85. doi: 10.1046/j.1469-1809.2003.00028.x.
5
Cystic fibrosis transmembrane conductance regulator-modifying medications: the future of cystic fibrosis treatment.囊性纤维化跨膜电导调节因子修饰药物:囊性纤维化治疗的未来。
Ann Pharmacother. 2012 Jul-Aug;46(7-8):1065-75. doi: 10.1345/aph.1R076. Epub 2012 Jun 26.
6
Genotype and phenotype in cystic fibrosis.囊性纤维化中的基因型与表型。
Respiration. 2000;67(2):117-33. doi: 10.1159/000029497.
7
Clinical implications of cystic fibrosis transmembrane conductance regulator mutations.囊性纤维化跨膜传导调节因子突变的临床意义
Clin Chest Med. 1998 Sep;19(3):443-58, v. doi: 10.1016/s0272-5231(05)70092-7.
8
Pharmacogenetics of cystic fibrosis treatment.囊性纤维化治疗的药物遗传学
Pharmacogenomics. 2016 Aug;17(13):1453-63. doi: 10.2217/pgs.16.25. Epub 2016 Aug 4.
9
Variant cystic fibrosis phenotypes in the absence of CFTR mutations.无CFTR基因突变时的囊性纤维化变异表型。
N Engl J Med. 2002 Aug 8;347(6):401-7. doi: 10.1056/NEJMoa011899.
10
[Cystic fibrosis modifying genes].[囊性纤维化修饰基因]
Pneumologie. 2005 Jun;59(6):395-404. doi: 10.1055/s-2004-830251.

引用本文的文献

1
Should atelectasis be considered a pulmonary complication and indicator of poor prognosis in cystic fibrosis?在囊性纤维化中,肺不张是否应被视为肺部并发症和预后不良的指标?
J Int Med Res. 2024 Mar;52(3):3000605241233520. doi: 10.1177/03000605241233520.
2
Impact of elexacaftor/tezacaftor/ivacaftor on depression and anxiety in cystic fibrosis.依洛尤单抗治疗对高胆固醇血症患者认知功能的影响。
Ther Adv Respir Dis. 2022 Jan-Dec;16:17534666221144211. doi: 10.1177/17534666221144211.
3
Chest radiography and computed tomography imaging in cystic fibrosis: current challenges and new perspectives.
囊性纤维化的胸部 X 线摄影和计算机断层成像:当前的挑战和新视角。
Pediatr Radiol. 2023 Apr;53(4):649-659. doi: 10.1007/s00247-022-05522-4. Epub 2022 Oct 29.
4
Editorial: Co-Infection and Consequences in Cystic Fibrosis.社论:囊性纤维化中的合并感染及其后果
Front Cell Infect Microbiol. 2022 Jun 1;12:924527. doi: 10.3389/fcimb.2022.924527. eCollection 2022.
5
Proteostasis Regulators in Cystic Fibrosis: Current Development and Future Perspectives.囊性纤维化中的蛋白稳态调节剂:现状与未来展望。
J Med Chem. 2022 Apr 14;65(7):5212-5243. doi: 10.1021/acs.jmedchem.1c01897. Epub 2022 Apr 4.
6
State-of-the-art review of lung imaging in cystic fibrosis with recommendations for pulmonologists and radiologists from the "iMAging managEment of cySTic fibROsis" (MAESTRO) consortium.肺囊性纤维化影像学的最新研究进展:来自“囊性纤维化的影像学管理”(MAESTRO)联合会的肺科医生和放射科医生的建议。
Eur Respir Rev. 2022 Mar 23;31(163). doi: 10.1183/16000617.0173-2021. Print 2022 Mar 31.
7
Frequency of CFTR variants in southern Brazil and indication for modulators therapy in patients with cystic fibrosis.巴西南部囊性纤维化跨膜传导调节因子(CFTR)变异的频率及对囊性纤维化患者进行调节剂治疗的指征
Genet Mol Biol. 2021 Dec 6;45(1):e20200275. doi: 10.1590/1678-4685-GMB-2020-0275. eCollection 2021.
8
The Bactericidal Tandem Drug, AB569: How to Eradicate Antibiotic-Resistant Biofilm in Multiple Disease Settings Including Cystic Fibrosis, Burns/Wounds and Urinary Tract Infections.杀菌串联药物AB569:如何在包括囊性纤维化、烧伤/伤口和尿路感染在内的多种疾病环境中根除抗生素耐药生物膜。
Front Microbiol. 2021 Jun 17;12:639362. doi: 10.3389/fmicb.2021.639362. eCollection 2021.
9
Review of Rapid Advances in Cystic Fibrosis.囊性纤维化的快速进展综述。
Mo Med. 2020 Nov-Dec;117(6):548-554.
10
High-resolution computed tomography findings in young infants with cystic fibrosis detected by newborn screening.新生儿筛查发现的囊性纤维化患儿的高分辨率计算机断层扫描表现。
Clinics (Sao Paulo). 2019 Oct 21;74:e1399. doi: 10.6061/clinics/2019/e1399. eCollection 2019.